A Phase III Study to Evaluate the Efficacy and Safety of JYP0322 in Previously Untreated ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer

A Phase III Study to Evaluate the Efficacy and Safety of JYP0322 in Previously Untreated ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer is a phase 3, randomised interventional study registered as NCT07816380 by Guangzhou JOYO Pharma Co., Ltd, with a registry enrolment figure of 216 participants, started 2026-10-30 and due to reach its primary completion in 2028-12-30. Interventions recorded: JYP0322 Tablets; Crizotinib Capsules. Conditions listed: NSCLC (Advanced Non-small Cell Lung Cancer). Primary outcome: Progression-Free Survival (PFS) assessed by Blinded Independent Central Review (BICR/BIRC) per RECIST v1.1. Lung eligibility wording from the registry: "Histologically or cytologically confirmed, unresectable locally advanced (AJCC 9th edition stage IIIB or IIIC not amenable to multimodality therapy) or metastatic (stage IV) ROS1-positive non-small cell lung cancer (NSCLC)". No results are recorded here; the registry entry is the source.